Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 7/20 | 0.51 |
| ▸ | OPRK1 | P41145 | 6/20 | 0.51 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.51 |
| ▸ | OGFRL1 | Q5TC84 | 2/20 | 0.51 |
| ▸ | OPRL1 | P41146 | 6/20 | 0.49 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.44 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12084315 | 0.88 | OPRM1 (0.52) | OPRM1OPRK1OPRD1OGFRL1OPRL1 | |
| SCHEMBL13203976 | 0.85 | OPRM1 (0.39) | OPRM1OPRK1OPRD1OGFRL1OPRL1 | |
| SCHEMBL8524452 | 0.80 | PDE7A (0.50) | OPRM1OPRK1OPRL1 | |
| SCHEMBL13203964 | 0.79 | CHRM1 (0.50) | — | |
| SCHEMBL12084593 | 0.79 | TNKS (0.44) | OPRM1OPRK1OPRD1OGFRL1OPRL1 | |
| SCHEMBL13203923 | 0.78 | KDM4E (0.42) | OPRM1OPRK1OPRL1SIGMAR1SLC18A3 | |
| SCHEMBL3816106 | 0.78 | SIGMAR1 (0.68) | OPRM1OPRL1SIGMAR1SLC18A3 | |
| SCHEMBL8213464 | 0.77 | CALCRL (0.43) | OPRM1OPRK1OPRD1OGFRL1OPRL1 | |
| SCHEMBL8221857 | 0.76 | CALCRL (0.46) | OPRM1OPRK1OPRD1OGFRL1OPRL1 | |
| SCHEMBL13203944 | 0.76 | CHRM1 (0.46) | OPRM1OPRK1OPRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7786107-B2 | Modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-08-31 | — | — | US | disclosed |
| US-7786107-B2 | Modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-08-31 | — | — | US | disclosed |
| US-7786107-B2 | Modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-08-31 | — | — | US | disclosed |
| US-20100063021-A9 | Modulators of muscarinic receptors | VERTEX PHARMACEUTICALS (SAN DIEGO) LLC | 2010-03-11 | — | — | US | disclosed |
| US-20100063021-A9 | Modulators of muscarinic receptors | VERTEX PHARMACEUTICALS (SAN DIEGO) LLC | 2010-03-11 | — | — | US | disclosed |
| US-20100063021-A9 | Modulators of muscarinic receptors | VERTEX PHARMACEUTICALS (SAN DIEGO) LLC | 2010-03-11 | — | — | US | disclosed |
| US-20080113958-A1 | Treating neurodegenerative diseases, psychological disorders, pain, glaucoma, dru eye, dry mouth, Sjogren's syndrome, asthma, bradycardia, wound healing, gastrointestinal disorders; compounds based on amide- or urea-functional 1,2,3,4-tetrahydrospiro[benzo[b]azepine-5,4'-piperidine] rings | VERTEX PHARMACEUTICALS INCORPORATED | 2008-05-15 | — | — | US | disclosed |
| US-20080113958-A1 | Treating neurodegenerative diseases, psychological disorders, pain, glaucoma, dru eye, dry mouth, Sjogren's syndrome, asthma, bradycardia, wound healing, gastrointestinal disorders; compounds based on amide- or urea-functional 1,2,3,4-tetrahydrospiro[benzo[b]azepine-5,4'-piperidine] rings | VERTEX PHARMACEUTICALS INCORPORATED | 2008-05-15 | — | — | US | disclosed |
| US-20080113958-A1 | Treating neurodegenerative diseases, psychological disorders, pain, glaucoma, dru eye, dry mouth, Sjogren's syndrome, asthma, bradycardia, wound healing, gastrointestinal disorders; compounds based on amide- or urea-functional 1,2,3,4-tetrahydrospiro[benzo[b]azepine-5,4'-piperidine] rings | VERTEX PHARMACEUTICALS INCORPORATED | 2008-05-15 | — | — | US | disclosed |
| WO-2008021545-A2 | MODULATORS OF MUSCARINIC RECEPTORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063021-A9 | Modulators of muscarinic receptors | CHRM3, CHRM5, CHRM2 | OPRM1 66/4885OPRK1 114/4885OPRD1 224/4885 |
| US-20080113958-A1 | Treating neurodegenerative diseases, psychological disorders, pain, glaucoma, dru eye, dry mouth, Sjogren's syndrome, asthma, bradycardia, wound healing, gastrointestinal disorders; compounds based on amide- or urea-functional 1,2,3,4-tetrahydrospiro[benzo[b]azepine-5,4'-piperidine] rings | HRH2, ACHE, CHRM2 | OPRM1 73/4885OPRK1 19/4885OPRD1 37/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.